Loading company…
Nuclidium develops copper-based radiopharmaceuticals for cancer diagnosis and treatment.
Nuclidium's CuTrace platform combines copper radiometals with cancer-targeting compounds. Its pipeline includes programs for prostate, breast, lung and other cancers. Founded in 2017, the company is based in Basel, Switzerland. It raised CHF 26 million in Series B funding in May 2026, co-led by Angelini Ventures and Kurma Partners.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in